NRG 5051
Alternative Names: NRG-5051Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator NRG Therapeutics
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Mitochondrial permeability transition pore inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 08 Nov 2024 Pharmacodynamics data from a preclinical study in Neurodegenerative disorders released byNRG Therapeutics
- 31 Oct 2024 Preclinical trials in Amyotrophic lateral sclerosis in United Kingdom (PO) prior to October 2024
- 31 Oct 2024 Preclinical trials in Parkinson's disease in United Kingdom (PO) prior to October 2024